跳至主要内容
临床试验/ACTRN12621001652864
ACTRN12621001652864招募中未知

The efficacy of treatment with focal irreversible electroporation for men with localised prostate cancer

A/Prof Nathan Lawrentschuk0 个研究点目标入组 100 人开始时间: 2021年12月1日最近更新:
适应症

试验速览

阶段
未知
状态
招募中
发起方
入组人数
100

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional
分配方式
Non-randomised trial
主要目的
Treatment
盲法
Open (masking not used)

入排标准

年龄范围
18 Years 至 o limit(—)
性别
Male

入选标准

  • 1)Primary prostate cancer (PCa) diagnosis
  • a.Gleason score less than or equal to 7 (grade group 3 or less)
  • b.Radiological stage T1-T3
  • c.No previous treatment for PCa
  • 2)Radio-recurrent prostate cancer
  • a.Radio-recurrent prostate cancer greater or equal to 2 years post LDR/PDR/HDR brachytherapy or EBRT
  • 3)Both groups
  • a.Imaging negative for metastatic disease
  • b.Radiological stage T1-T3
  • c.Lesion visible on prostate MRI
  • d.Unilateral or single midline anterior/posterior index tumour, allowing single targeted ablative therapy
  • e.Lesion confirmed with targeted prostate biopsy
  • f.Life expectancy over 10 years
  • g.No previous androgen suppression/hormone treatment for PCa
  • h.Can give written consent in English

排除标准

  • Biopsy proven lymph node involvement
  • Metastatic disease
  • Bowel disease (e.g. IBD)
  • Previous transurethral resection of the prostate (TURP)
  • Inability to undergo mpMRI
  • Incompatible metallic implants
  • Claustrophobia
  • Men unable to tolerate transrectal ultrasound
  • Men who have undergone previous focal therapy to the prostate
  • oHIFU, IRE, cryosurgery, thermal, microwave, laser therapy
  • Men who have received androgen suppression/hormone treatment within the last 6 months
  • Metallic implants or stents in urethra
  • Histological evidence of any cancer in more than one area of the prostate
  • Requires simultaneous urological procedure at time of salvage IRE (e.g. mini-TUR)

研究者

发起方
A/Prof Nathan Lawrentschuk

相似试验